JP Morgan Downgrades Atea Pharmaceuticals to Underweight
Portfolio Pulse from richadhand@benzinga.com
JP Morgan analyst Eric Joseph has downgraded Atea Pharmaceuticals (NASDAQ:AVIR) from Neutral to Underweight.

August 10, 2023 | 9:29 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Atea Pharmaceuticals has been downgraded from Neutral to Underweight by JP Morgan, which could negatively impact the stock's performance.
Analyst ratings often influence investor sentiment and can impact a stock's price. A downgrade from Neutral to Underweight suggests that the analyst believes the stock will underperform compared to others, which could lead to a decrease in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100